This paper is a summary of Blue Matter Breakfast Club meeting #14. Our guest speakers were Frederic Prince, PhD, Project Team Leader, Early Development (previously General Manager, France, bluebird bio) and Oswald Bentinck, Head of Value & Access, Rocket Pharmaceuticals (previously Head of Market Access, Gene Therapies, EMEA at Novartis and AveXis). The discussion was moderated by Dirk Moritz, PhD, Senior Adviser for Blue Matter. Our panel discussed the current state of gene therapy and where it’s heading in the coming decades.
